nach oben

Endocrine

Erschienen in:

01.05.2015 | Original Article

Effects of intensive glycemic control in ocular complications in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

verfasst von: Xiaodan Zhang, Jiangpei Zhao, Tongfeng Zhao, Huanliang Liu

Erschienen in: Endocrine | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Whether intensive glycemic control can reduce incidence of diabetic retinopathy or other diabetes-associated ocular complications remains undefined. In this meta-analysis, we assessed the effects of intensive versus conventional glycemic control in ocular complications in patients with type 2 diabetes. A systematic literature search of PubMed, Web of Knowledge, and Scopus (until December 12, 2013) was conducted. Randomized controlled trials which compared intensive glycemic control with conventional glycemic control in ocular events in patients with type 2 diabetes were included. Random-effects models were used to measure the pooled odds ratio (OR) with 95 % confidence interval (CI). Seven trials involving 32,523 patients were included. Intensive glycemic control reduced the risks of retinal photocoagulation or vitrectomy (OR 0.86; 95 % CI 0.75–0.98), macular edema (OR 0.65; 95 % CI 0.43–0.99), and progression of retinopathy (OR 0.69; 95 % CI 0.55–0.87). No significant risk reduction was shown in incidence of retinopathy (OR 0.67; 95 % CI 0.26–1.73), cataract surgery (OR 0.88; 95 % CI 0.76–1.03), or severe loss of vision or blindness (OR 0.99; 95 % CI 0.86–1.13). Intensive glycemic control reduces the risk of most retinopathy-related events. But no beneficial effect was shown in ocular endpoint as severe loss of vision or blindness.

Nur mit Berechtigung zugänglich

B.E. Klein, Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic. Epidemiol. 14, 179–183 (2007)CrossRefPubMed

D.A. Antonetti, R. Klein, T.W. Gardner, Diabetic retinopathy. N. Engl. J. Med. 366, 1227–1239 (2012)CrossRefPubMed

J.W. Yau, S.L. Rogers, R. Kawasaki, E.L. Lamoureux, J.W. Kowalski, T. Bek, S.J. Chen, J.M. Dekker, A. Fletcher, J. Grauslund, S. Haffner, R.F. Hamman, M.K. Ikram, T. Kayama, B.E. Klein, R. Klein, S. Krishnaiah, K. Mayurasakorn, J.P. O’Hare, T.J. Orchard, M. Porta, M. Rema, M.S. Roy, T. Sharma, J. Shaw, H. Taylor, J.M. Tielsch, R. Varma, J.J. Wang, N. Wang, S. West, L. Xu, M. Yasuda, X. Zhang, P. Mitchell, T.Y. Wong, Meta-Analysis for Eye Disease (META-EYE) Study Group, Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35, 556–564 (2012)CrossRefPubMedCentralPubMed

E.L. Lamoureux, T.Y. Wong, Diabetic retinopathy in 2011: further insights from new epidemiological studies and clinical trials. Diabetes Care 34, 1066–1067 (2011)CrossRefPubMedCentralPubMed

Y.J. Cheng, E.W. Gregg, L.S. Geiss, G. Imperatore, D.E. Williams, X. Zhang, A.L. Albright, C.C. Cowie, R. Klein, J.B. Saaddine, Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population Implications for diabetes diagnostic thresholds. Diabetes Care 32, 2027–2032 (2009)CrossRefPubMedCentralPubMed

H.T. Nguyen, S.D. Luzio, J. Dolben, J. West, L. Beck, P.A. Coates, D.R. Owens, Dominant risk factors for retinopathy at clinical diagnosis in patients with type II diabetes mellitus. J. Diabetes Complications 10, 211–219 (1996)CrossRefPubMed

R. Klein, B.E. Klein, S.E. Moss, K.J. Cruickshanks, Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch. Intern. Med. 154, 2169–2178 (1994)CrossRefPubMed

T. Shiraiwa, H. Kaneto, T. Miyatsuka, K. Kato, K. Yamamoto, A. Kawashima, T. Kanda, M. Suzuki, E. Imano, M. Matsuhisa, M. Hori, Y. Yamasaki, Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 28, 2806–2807 (2005)CrossRefPubMed

X.W. Xie, L. Xu, Y.X. Wang, J.B. Jonas, Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes. Arch. Clin. Exp. Ophthalmol. 246, 1519–1526 (2008)CrossRefPubMed

10.

M.S. Roy, M. Affouf, Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. Arch. Ophthalmol. 124, 1297–1306 (2006)CrossRefPubMed

11.

R. Klein, K.E. Lee, R.E. Gangnon, B.E. Klein, The 25-year incidence of visual impairment in type 1 diabetes mellitus: the wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 117, 63–70 (2010)CrossRefPubMedCentralPubMed

12.

M. Heniricsson, L. Nyström, G. Blohmé, J. Ostman, C. Kullberg, M. Svensson, A. Schölin, H.J. Arnqvist, E. Björk, J. Bolinder, J.W. Eriksson, G. Sundkvist, The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26, 349–354 (2003)CrossRef

13.

F. Ismail-Beigi, T. Craven, M.A. Banerji, J. Basile, J. Calles, R.M. Cohen, R. Cuddihy, W.C. Cushman, S. Genuth, R.H. Grimm, B.P. Hamilton, B. Hoogwerf, D. Karl, L. Katz, A. Krikorian, P. O’Connor, R. Pop-Busui, U. Schubart, D. Simmons, H. Taylor, A. Thomas, D. Weiss, I. Hramiak, ACCORD trial group, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419–430 (2010)CrossRefPubMedCentralPubMed

14.

A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, S. Heller, L. Liu, G. Mancia, C.E. Mogensen, C. Pan, N. Poulter, A. Rodgers, B. Williams, S. Bompoint, B.E. de Galan, R. Joshi, F. Travert, ADVANCE Collaborative Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008)CrossRefPubMed

15.

M. Shichiri, H. Kishikawa, Y. Ohkubo, N. Wake, Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23, B21–B29 (2000)PubMed

16.

UK Propective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998)CrossRef

17.

N. Emanuele, R. Klein, C. Abraira, J. Colwell, J. Comstock, W.G. Henderson, S. Levin, F. Nuttall, C. Sawin, C. Silbert, H.S. Lee, N. Johnson-Nagel, Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care 19, 1375–1381 (1996)CrossRefPubMed

18.

W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, P.D. Reaven, F.J. Zieve, J. Marks, S.N. Davis, R. Hayward, S.R. Warren, S. Goldman, M. McCarren, M.E. Vitek, W.G. Henderson, G.D. Huang, VADT investigators, glucose control and vascular complications in veterans with type 2 diabetes. N. Eng. J. Med. 360, 129–139 (2009)CrossRef

19.

O. Brinchmann-Hansen, K. Dahl-Jørgensen, L. Sandvik, K.F. Hanssen, Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ 304, 19–22 (1992)CrossRefPubMedCentralPubMed

20.

P. Reichard, B.Y. Nilsson, U. Rosenqvist, The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 329, 304–309 (1993)CrossRefPubMed

21.

N.H. White, W. Sun, P.A. Cleary, R.P. Danis, M.D. Davis, D.P. Hainsworth, L.D. Hubbard, J.M. Lachin, D.M. Nathan, Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch. Ophthalmol. 126, 1707–1715 (2008)CrossRefPubMed

22.

J.P.T. Higgins, S. Green, Cochrane handbook for systematic reviews of intervention 5.1.0 (2011) Cochrane Collaboration. [Online] Available from http://handbook.cochrane.org. Accessed 20 December 2013

23.

D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009)CrossRefPubMedCentralPubMed

24.

T. Zhao, J. Zhao, Association of the apolipoprotein A5 gene -1131 T > C polymorphism with fasting blood lipids: a meta-analysis in 37859 subjects. BMC Med. Genet. 11, 120 (2010)CrossRefPubMedCentralPubMed

25.

J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327, 557–560 (2003)CrossRefPubMedCentralPubMed

26.

E.Y. Chew, W.T. Ambrosius, M.D. Davis, R.P. Danis, S. Gangaputra, C.M. Greven, L. Hubbard, B.A. Esser, J.F. Lovato, L.H. Perdue, D.C. Goff, W.C. Cushman, H.N. Ginsberg, M.B. Elam, S. Genuth, H.C. Gerstein, U. Schubart, L.J. Fine, ACCORD Study Group, ACCORD Eye Study Group, Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med 363, 233–244 (2010)CrossRefPubMed

27.

J.W. Beulens, A. Patel, J.R. Vingerling, J.K. Cruickshank, A.D. Hughes, A. Stanton, J. Lu, S.A. McG Thom, D.E. Grobbee, R.P. Stolk, Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetologia 52, 2027–2036 (2009)CrossRefPubMed

28.

UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998)CrossRef

29.

Early Treatment Diabetic Retinopathy Study Research Group, Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98, 786–806 (1991)CrossRef

30.

Early Treatment Diabetic Retinopathy Study Research Group, Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98, 823–833 (1991)CrossRef

31.

P.H. Wang, J. Lau, T.C. Chalmers, Metaanalysis of the effects of intensive glycemic control on late complications of type I diabetes mellitus. Lancet 341, 1306–1309 (1993)CrossRefPubMed

32.

L.P. Aiello, DCCT/EDIC Research Group, Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37, 17–23 (2014)CrossRefPubMedCentralPubMed

33.

A.M. Buehler, A.B. Cavalcanti, O. Berwanger, M. Figueiro, L.N. Laranjeira, A.D. Zazula, B. Kioshi, D.G. Bugano, E. Santucci, G. Sbruzzi, H.P. Guimaraes, V.O. Carvalho, S.A. Bordin, Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of RCTs. Cardiovasc. Ther. 31, 147–160 (2013)CrossRefPubMed

34.

B. Hemmingsen, S.S. Lund, C. Gluud, A. Vaag, T. Almdal, C. Hemmingsen, J. Wetterslev, Intensive glycaemic control for patients with T2DM: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343, d6898 (2011)CrossRefPubMedCentralPubMed

35.

The Diabetes Control and Complications Trial Research Group, Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch. Ophthalmol. 116, 874–886 (1998)CrossRef

36.

E. Moskalets, G. Galstyan, E. Starostina, M. Antsiferov, E. Chantelau, Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J. Diabetes Complications 8, 45–50 (1994)CrossRefPubMed

37.

M. Henricsson, A. Nilsson, L. Janzon, L. Groop, The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet. Med. 14, 123–131 (1997)CrossRefPubMed

38.

M. Henricsson, K. Berntorp, E. Berntorp, P. Fernlund, G. Sundkvist, Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables. Diabetes Care 22, 1944–1949 (1999)CrossRefPubMed

39.

J. Tovi, S.O. Ingemansson, P. Engfeldt, Insulin treatment of elderly type 2 diabetic patients: effects on retinopathy. Diabetes Metab. 24, 442–447 (1998)PubMed

40.

S. Savage, R.O. Estacio, B. Jeffers, R.W. Schrier, Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. Proc. Assoc. Am. Physicians 109, 181–189 (1997)PubMed

41.

E. Chantelau, E.M. Kohner, Why some cases of retinopathy worsen when diabetic control improves. BMJ 315, 1105–1106 (1997)CrossRefPubMedCentralPubMed

42.

M. Paques, P. Massin, A. Gaudric, Growth factors and diabetic retinopathy. Diabetes Metab. 23, 125–130 (1997)PubMed

43.

R. Simó, J.M. Sundstrom, D.A. Antonetti, Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 37, 893–899 (2014)CrossRefPubMed

44.

The Kroc Collaborative Study Group, Follow-up of the Kroc Collaborative Study, Diabetic retinopathy after two years of intensified insulin treatment. JAMA 260, 37–41 (1988)CrossRef

45.

E.Y. Chew, W.T. Ambrosius, R.P. Danis, Retinopathy progression in type 2 diabetes. N. Engl. J. Med. 25, 2173–2174 (2010)

46.

Diabetes Control and Complications Trial Research Group, Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 102, 647–661 (1995)CrossRef

47.

R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-year follow-up of intensive glucose control in type 2 diabetes. N. Eng. J. Med. 359, 1577–1589 (2008)CrossRef

48.

Diabetes Control and Complications Trail Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Eng. J. Med. 329, 977–986 (1993)CrossRef

49.

N. Cheung, P. Mitchell, T.Y. Wong, Diabetic retinopathy. Lancet 376, 124–136 (2010)CrossRefPubMed

50.

V.S. Jeganathan, J.J. Wang, T.Y. Wong, Ocular association of diabetes other than diabetic retinopathy. Diabetes Care 31, 1905–1912 (2008)CrossRefPubMedCentralPubMed

51.

C. Rotimi, H. Daniel, J. Zhou, A. Obisesan, G. Chen, Y. Chen, A. Amoah, V. Opoku, J. Acheampong, K. Agyenim-Boateng, B.A. Eghan, J. Oli, G. Okafor, E. Ofoegbu, B. Osotimehin, F. Abbiyesuku, T. Johnson, O. Fasanmade, A. Doumatey, T. Aje, F. Collins, G. Dunston, Prevalence and determinants of diabetic retinopathy and cataracts in West African type 2 diabetes patients. Ethn. Dis. 13, S110–S117 (2003)PubMed

52.

B. Sonmez, B. Bozkurt, A. Atmaca, M. Irkec, M. Orhan, U. Aslan, Effect of glycemic control on refractive changes in diabetic patients with hyperglycemia. Cornea 24, 531–537 (2005)CrossRefPubMed

53.

S. Kato, T. Oshika, J. Numaga, H. Kawashima, S. Kitano, T. Kaiya, Influence of rapid glycemic control on lens opacity in patients with diabetes mellitus. Am. J. Ophthalmol. 130, 354–355 (2000)CrossRefPubMed

54.

K. Skarbez, Y. Priestley, M. Hoepf, S.B. Koevary, Comprehensive review of the effects of diabetes on ocular health. Expert Rev. Ophthalmol. 5, 557–577 (2010)CrossRefPubMedCentralPubMed

55.

American Diabetes Association, Executive summary: standards of medical care in diabetes-2009. Diabetes Care 32, S6–S12 (2009)CrossRef

56.

P.S. Jellinger, J.A. Davidson, L. Blonde, D. Einhorn, G. Grunberger, Y. Handelsman, R. Hellman, H. Lebovitz, P. Levy, V.L. Roberts, ACE/AACE Diabetes Road MapTask Force, Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr. Pract. 13, 260–268 (2007)CrossRefPubMed

Titel: Effects of intensive glycemic control in ocular complications in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
verfasst von: Xiaodan Zhang
Jiangpei Zhao
Tongfeng Zhao
Huanliang Liu
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0459-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Thyroxine softgel capsule in patients with gastric-related T4 malabsorption

Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis

Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial

Comparison of the effect of ‘metabolically healthy but obese’ and ‘metabolically abnormal but not obese’ phenotypes on development of diabetes and cardiovascular disease in Chinese

Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience